Our Partners



Bill & Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of co-chairs Bill Gates and Melinda French Gates and the board of trustees.


Tsinghua University

Established in 1911, Tsinghua University is widely acknowledged and consistently ranked as the top academic and research institution in China, while also enjoying a global reputation. It has a strong foundation in biomedical research, including life sciences, basic medical sciences, biomedical engineering, chemistry and information technology.

The School of Pharmaceutical Sciences (SPS) is Tsinghua’s correspondent collaborator for GHDDI, providing various resources to support the development of the Institute, such as research collaboration, talent recruitment, and operation management.

http://www.tsinghua.edu.cn/ http://www.sps.tsinghua.edu.cn/

Beijing Municipal Science and Technology Commission

Beijing Municipal Government has been actively promoting pharmaceutical innovations in small molecule drug, Chinese traditional medicine, biologics and medical device by providing significant financial, regulatory and talent development support. Through an innovative Public-Private Partnership (PPP) model, Beijing Municipal Science and Technology Commission supports GHDDI with grants and policy innovations, which is also facilitated by Beijing Municipal Bureau of Finance, Beijing Municipal Bureau of Civil Affairs, Haidian District Government and Dongsheng Township Government.


Partnership Network

GHDDI is dedicated to creating a comprehensive and interconnected industry chain for new drug research and development on a global scale. This goal is achieved through the establishment of collaborations with over 40 of the world's top scientific research institutes, pharmaceutical and biotechnology companies, technology enterprises, and disease alliances across different fields. GHDDI is the first Chinese member organization joining MalDA and the only representative in Asia at CARE.